For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of ...

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

Weight-loss drug developer Zealand Pharma said it halted work on an early-stage obesity treatment candidate to focus on more promising programs, including one for which it teamed up with Swiss giant ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Managing obesity with both drugs and lifestyle changes ‘enables clinicians to treat patients holistically, long-term, and in ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...